315 related articles for article (PubMed ID: 34575992)
81. Detection of anti-asparaginase antibodies during therapy with E.coli asparaginase in children with newly diagnosed acute lymphoblastic leukemia and lymphoma.
Ebeid EN; Kamel MM; Ali BA
J Egypt Natl Canc Inst; 2008 Jun; 20(2):127-33. PubMed ID: 20029468
[TBL] [Abstract][Full Text] [Related]
82. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
[TBL] [Abstract][Full Text] [Related]
83. Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.
Dinner S; Lee D; Liedtke M
Leuk Lymphoma; 2014 Aug; 55(8):1715-24. PubMed ID: 24251864
[TBL] [Abstract][Full Text] [Related]
84. Gastrointestinal microbial populations can distinguish pediatric and adolescent Acute Lymphoblastic Leukemia (ALL) at the time of disease diagnosis.
Rajagopala SV; Yooseph S; Harkins DM; Moncera KJ; Zabokrtsky KB; Torralba MG; Tovchigrechko A; Highlander SK; Pieper R; Sender L; Nelson KE
BMC Genomics; 2016 Aug; 17(1):635. PubMed ID: 27527070
[TBL] [Abstract][Full Text] [Related]
85. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
Burkhardt B; Reiter A; Landmann E; Lang P; Lassay L; Dickerhoff R; Lakomek M; Henze G; von Stackelberg A
J Clin Oncol; 2009 Jul; 27(20):3363-9. PubMed ID: 19433688
[TBL] [Abstract][Full Text] [Related]
86. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
[TBL] [Abstract][Full Text] [Related]
87. Trends in survival of leukemia among children, adolescents, and young adults: A population-based study in Osaka, Japan.
Nakata K; Okawa S; Fuji S; Sato A; Morishima T; Tada Y; Inoue M; Hara J; Kawa K; Miyashiro I;
Cancer Sci; 2021 Mar; 112(3):1150-1160. PubMed ID: 33428808
[TBL] [Abstract][Full Text] [Related]
88. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
Front Immunol; 2018; 9():239. PubMed ID: 29515572
[TBL] [Abstract][Full Text] [Related]
89. Novel Biomarkers and Molecular Targets in ALL.
De Sa H; Leonard J
Curr Hematol Malig Rep; 2024 Feb; 19(1):18-34. PubMed ID: 38048037
[TBL] [Abstract][Full Text] [Related]
90. Novel drug targets in acute leukemia.
Stock W
Clin Adv Hematol Oncol; 2015 Aug; 13(8):493-5. PubMed ID: 26351809
[No Abstract] [Full Text] [Related]
91. Precision medicine in acute lymphoblastic leukemia.
Pui CH
Front Med; 2020 Dec; 14(6):689-700. PubMed ID: 33074527
[TBL] [Abstract][Full Text] [Related]
92. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
Escherich G; Tröger A; Göbel U; Graubner U; Pekrun A; Jorch N; Kaspers G; Zimmermann M; zur Stadt U; Kazemier K; Pieters R; Den Boer ML; Horstmann M; Janka GE;
Haematologica; 2011 Jun; 96(6):854-62. PubMed ID: 21330320
[TBL] [Abstract][Full Text] [Related]
93. Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.
Mathisen MS; Jabbour E; Kantarjian HM
Oncology (Williston Park); 2012 Sep; 26(9):851-9. PubMed ID: 23061343
[TBL] [Abstract][Full Text] [Related]
94. [II. New Treatment Option for Acute Lymphoblastic Leukemia].
Makiyama J; Tojo A
Gan To Kagaku Ryoho; 2018 May; 45(5):801-805. PubMed ID: 30026441
[No Abstract] [Full Text] [Related]
95. Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development.
Lee-Sherick AB; Linger RM; Gore L; Keating AK; Graham DK
Br J Haematol; 2010 Nov; 151(4):295-311. PubMed ID: 20813012
[TBL] [Abstract][Full Text] [Related]
96. Acute lymphoblastic leukemia in adolescents and young adults in Finland.
Usvasalo A; Räty R; Knuutila S; Vettenranta K; Harila-Saari A; Jantunen E; Kauppila M; Koistinen P; Parto K; Riikonen P; Salmi TT; Silvennoinen R; Elonen E; Saarinen-Pihkala UM
Haematologica; 2008 Aug; 93(8):1161-8. PubMed ID: 18556413
[TBL] [Abstract][Full Text] [Related]
97. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
98. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
Tasian SK; Hunger SP
Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
[TBL] [Abstract][Full Text] [Related]
99. Acute Leukemia in Infants.
Ibrahimova A; Pommert L; Breese EH
Curr Oncol Rep; 2021 Feb; 23(3):27. PubMed ID: 33580326
[TBL] [Abstract][Full Text] [Related]
100. Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?
Pui CH; Mullighan CG; Evans WE; Relling MV
Blood; 2012 Aug; 120(6):1165-74. PubMed ID: 22730540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
